Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/31852
Title: Does long-term phenytoin have a place in Dravet syndrome?
Austin Authors: Zographos, George A;Russ-Hall, Sophie J;Scheffer, Ingrid E 
Affiliation: Epilepsy Research Centre
Medicine (University of Melbourne)
Issue Date: Dec-2022
Date: 2022
Publication information: Annals of Clinical and t Translational Neurology 2022; 9(12)
Abstract: Anti-seizure medications that block sodium channels are generally considered contraindicated in Dravet syndrome. There is, however, considerable debate about the sodium-channel blocker phenytoin, which is often used for status epilepticus, a frequent feature of Dravet syndrome. We describe four patients with Dravet syndrome in whom long-term phenytoin therapy reduced seizure frequency and duration. In two patients, phenytoin produced prolonged periods without status epilepticus for the first time. Attempting to wean phenytoin in all patients after 1 to 20 years of use resulted in seizure exacerbation. Reintroducing phenytoin improved seizure control, suggesting phenytoin is beneficial in some patients with Dravet syndrome.
URI: https://ahro.austin.org.au/austinjspui/handle/1/31852
DOI: 10.1002/acn3.51684
ORCID: 0000-0002-8768-9757
0000-0002-4809-9340
0000-0002-2311-2174
Journal: Annals of Clinical and t Translational Neurology
Start page: 2036
End page: 2040
PubMed URL: 36314457
ISSN: 2328-9503
Type: Journal Article
Subjects: Phenytoin/pharmacology
Phenytoin/therapeutic use
Epilepsies, Myoclonic/drug therapy
Status Epilepticus/drug therapy
Appears in Collections:Journal articles

Show full item record

Page view(s)

22
checked on May 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.